Inclusion Criteria:

          -  Participants must have c-Met overexpression (c-Met+) non-small cell lung cancer
             (NSCLC) as assessed by an AbbVie designated immunohistochemistry (IHC) laboratory.

          -  Archival or fresh tumor material must be submitted for assessment of c-Met levels
             during the Pre-Screening period.

          -  A histologically documented non-squamous cell NSCLC that is locally advanced or
             metastatic.

          -  A known epidermal growth factor receptor (EGFR) activating mutation status.

          -  Actionable alterations in genes other than EGFR .

          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version
             1.1.

          -  An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.

          -  Have received no more than 1 line of prior systemic cytotoxic chemotherapy in the
             locally advanced or metastatic setting.

               -  Neoadjuvant and adjuvant systemic cytotoxic chemotherapy will count as a prior
                  line for eligibility purposes if progression occurred within 6 months of the end
                  of therapy.

          -  Have progressed on at least 1 line of prior therapy for locally advanced/metastatic
             NSCLC:

               -  Participants WITH an actionable gene alteration (e.g., anaplastic lymphoma kinase
                  [ALK] translocation): must have progressed on (or be considered ineligible for)
                  anti-cancer therapy targeting driver gene alterations and systemic cytotoxic
                  chemotherapy.

               -  Participants WITHOUT an actionable gene alteration: must have progressed on (or
                  be considered ineligible for) systemic cytotoxic chemotherapy and immune
                  checkpoint inhibitor (as monotherapy or in combination with chemotherapy).

          -  Participants with metastases to the central nervous system (CNS) are eligible only
             after definitive therapy (such as surgery or radiotherapy) is provided and:

               -  There is no evidence of progression of CNS metastases at least 4 weeks after
                  definitive therapy.

               -  They are asymptomatic and off or on a stable or reducing dose of systemic
                  steroids and/or anticonvulsants for at least 2 weeks prior to first dose of
                  telisotuzumab vedotin.

        Exclusion Criteria:

          -  Participants with adenosquamous histology.

          -  Actionable epidermal growth factor receptor (EGFR) activating mutations.

          -  Participants who have received prior c-Met-targeted antibodies.

          -  A history of other malignancies except:

               -  Malignancy treated with curative intent and with no known active disease present
                  for ≥2 years before the first dose of study drug and felt to be at low risk for
                  recurrence by investigator.

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease.

               -  Adequately treated carcinoma in situ without current evidence of disease.

          -  A history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of
             active pneumonitis on screening chest computed tomography (CT) scan. A history of
             prior radiation pneumonitis in the radiation field (fibrosis) is permitted.

          -  Unresolved clinically significant adverse event (AE) >= Grade 2 from prior anticancer
             therapy, except for alopecia or anemia.

          -  Major surgery within 21 days prior to the first dose of telisotuzumab vedotin.

          -  Clinically significant condition(s) as listed in the protocol.